Header Logo
Last Name

You can now add alternative names! Click here to add other names that you've published under.


Search Results to Michael Birrer

This is a "connection" page, showing the details of why an item matched the keywords from your search.


One or more keywords matched the following items that are connected to Birrer, Michael

Item TypeName
Academic Article Identification of novel therapeutic targets in microdissected clear cell ovarian cancers.
Concept Treatment Failure
Concept Treatment Outcome
Academic Article Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer.
Academic Article Targeting the Nuclear Import Receptor Kpnß1 as an Anticancer Therapeutic.
Academic Article A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer.
Academic Article Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.
Academic Article A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Academic Article Better therapeutic trials in ovarian cancer.
Academic Article "Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities".
Academic Article Dicer, Drosha, and outcomes in patients with ovarian cancer.
Academic Article BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Academic Article Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Academic Article Novel therapeutic targets.
Academic Article Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential.
Academic Article A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study.
Academic Article Ovarian cancer: markers of response.
Academic Article Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
Academic Article Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus.
Academic Article Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.
Academic Article Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer.
Academic Article FGF18 as a prognostic and therapeutic biomarker in ovarian cancer.
Academic Article Antibody-Drug Conjugate-Based Therapeutics: State of the Science.
Academic Article IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.
Academic Article A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
Academic Article Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target.
Academic Article Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance.
Academic Article Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer.
Academic Article Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.
Academic Article Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.
Academic Article Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors.
Academic Article Advances in the diagnosis and treatment of uterine sarcomas.
Academic Article Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
Academic Article Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study.
Academic Article Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials.
Academic Article Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses.
Academic Article Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Academic Article Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.
Academic Article NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide.
Academic Article Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
Academic Article Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies.
Academic Article Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Academic Article Ovarian Cancer Maintenance: Practice-Changing Data Calls for Changing Practice.
Academic Article Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer.
Academic Article Time for action: a "sea change" in treatment strategies for rare types of epithelial ovarian cancer.
Academic Article Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models.
Academic Article A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Grant The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer
Grant The Molecular Genetics of Gynecologic Cancers
Grant Validation of a genomic signature that predicts for sub-optimal debulking of epithelial ovarian cancer
Grant Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit
Grant Novel Biomarkers in Ovarian Cancer
Grant Genomic Stratification of Ovarian Cancer Patients
Academic Article Stent placement in ostial and nonostial atherosclerotic renal arterial stenoses: a prospective follow-up study.
Academic Article Treatment of renal artery fibromuscular dysplasia with balloon angioplasty: a prospective follow-up study.
Academic Article Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
Academic Article Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062).
Academic Article Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
Grant The Genomic, Epigenomic, and Quality-of-Life Characteristics of Long-Term Survivors of Ovarian Cancer
Academic Article Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
Academic Article The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-ß and PD-L1 Pathways.

Search Criteria
  • Therapeutics